A review on the molecular diagnostics of Lynch syndrome: A central role for the pathology laboratory

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 1-2, 2010, Pages 181-197

  van Lier, Margot G F ^a   Wagner, Anja ^a   van Leerdam, Monique E ^a   Biermann, Katharina ^b   Kuipers, Ernst J ^a   Steyerberg, Ewout W ^a   Dubbink, Hendrikus Jan ^b   Dinjens, Winand N M ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

BRAF mutation analysis; Immunohistochemistry; Lynch syndrome; Mismatch repair genes; MLH1 promoter methylation assay; Molecular pathology; MSI analysis; Review

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; MLH1 PROTEIN, HUMAN; NUCLEAR PROTEIN; PROTEIN MSH2; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

COLORECTAL TUMOR; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; MISMATCH REPAIR; MOLECULAR PATHOLOGY; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; COLORECTAL NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA MISMATCH REPAIR; DNA MUTATIONAL ANALYSIS; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GERM-LINE MUTATION; HUMANS; MUTS HOMOLOG 2 PROTEIN; NUCLEAR PROTEINS; PATHOLOGY, MOLECULAR; PROTO-ONCOGENE PROTEINS B-RAF; RISK FACTORS;

EID: 77951970005     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00977.x     Document Type: Review

References (133)

1. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol. 2005, 16:481-8.
2. Aaltonen LA, Salovaara R, Kristo P. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med. 1998, 338:1481-7.
3. Hampel H, Frankel WL, Martin E. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol. 2008, 26:5783-8.
4. Hampel H, Frankel W, Panescu J. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res. 2006, 66:7810-7.
5. Lynch HT, Smyrk TC, Watson P. Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology. 1993, 104:1535-49.
6. Watson P, Lynch HT. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer. 1993, 71:677-85.
7. Quehenberger F, Vasen HF, van Houwelingen HC. Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment. J Med Genet. 2005, 42:491-6.
8. Vasen HF, Wijnen JT, Menko FH. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology. 1996, 110:1020-7.
9. Plaschke J, Engel C, Kruger S. Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium. J Clin Oncol. 2004, 22:4486-94.
10. Aarnio M, Sankila R, Pukkala E. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer. 1999, 81:214-8.
11. Vasen HF, Stormorken A, Menko FH. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol. 2001, 19:4074-80.
12. Hendriks YM, Wagner A, Morreau H. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology. 2004, 127:17-25.
13. Hampel H, Stephens JA, Pukkala E. Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology. 2005, 129:415-21.
14. Senter L, Clendenning M, Sotamaa K. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology. 2008, 135:419-28.
15. Lynch HT, de la Chapelle A. Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet. 1999, 36:801-18.
16. Boland CR. Evolution of the nomenclature for the hereditary colorectal cancer syndromes. Fam Cancer. 2005, 4:211-8.
17. Jarvinen HJ, Aarnio M, Mustonen H. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 2000, 118:829-34.
18. de Jong AE, Hendriks YM, Kleibeuker JH. Decrease in mortality in Lynch syndrome families because of surveillance. Gastroenterology. 2006, 130:665-71.
19. Stupart DA, Goldberg PA, Algar U. Surveillance colonoscopy improves survival in a cohort of subjects with a single mismatch repair gene mutation. Colorectal Dis. 2009, 11:126-30.
20. Schmeler KM, Lynch HT, Chen LM. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med. 2006, 354:261-9.
21. Vasen HF, Mecklin JP, Khan PM. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum. 1991, 34:424-5.
22. Kievit W, de Bruin JH, Adang EM. Current clinical selection strategies for identification of hereditary non-polyposis colorectal cancer families are inadequate: a meta-analysis. Clin Genet. 2004, 65:308-16.
23. Vasen HF, Watson P, Mecklin JP. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology. 1999, 116:1453-6.
24. Lindor NM, Petersen GM, Hadley DW. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA. 2006, 296:1507-17.
25. Church J, McGannon E. Family history of colorectal cancer: how often and how accurately is it recorded. Dis Colon Rectum. 2000, 43:1540-4.
26. Katballe N, Juul S, Christensen M. Patient accuracy of reporting on hereditary non-polyposis colorectal cancer-related malignancy in family members. Br J Surg. 2001, 88:1228-33.
27. Sijmons RH, Boonstra AE, Reefhuis J. Accuracy of family history of cancer: clinical genetic implications. Eur J Hum Genet. 2000, 8:181-6.
28. Rodriguez-Bigas MA, Boland CR, Hamilton SR. A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst. 1997, 89:1758-62.
29. Umar A, Boland CR, Terdiman JP. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004, 96:261-8.
30. Jenkins MA, Hayashi S, O'Shea AM. Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastroenterology. 2007, 133:48-56.
31. Truta B, Chen YY, Blanco AM. Tumor histology helps to identify Lynch syndrome among colorectal cancer patients. Fam Cancer. 2008, 7:267-74.
32. Sanchez JA, Vogel JD, Kalady MF. Identifying Lynch syndrome: we are all responsible. Dis Colon Rectum. 2008, 51:1750-6.
33. Wolf B, Gruber S, Henglmueller S. Efficiency of the revised Bethesda guidelines (2003) for the detection of mutations in mismatch repair genes in Austrian HNPCC patients. Int J Cancer. 2006, 118:1465-70.
34. Pinol V, Castells A, Andreu M. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA. 2005, 293:1986-94.
35. Rodriguez-Moranta F, Castells A, Andreu M. Clinical performance of original and revised Bethesda guidelines for the identification of MSH2/MLH1 gene carriers in patients with newly diagnosed colorectal cancer: proposal of a new and simpler set of recommendations. Am J Gastroenterol. 2006, 101:1104-11.
36. Balmana J, Balaguer F, Castellvi-Bel S. Comparison of predictive models, clinical criteria and molecular tumour screening for the identification of patients with Lynch syndrome in a population-based cohort of colorectal cancer patients. J Med Genet. 2008, 45:557-63.
37. Ramsoekh D, Wagner A, van Leerdam ME. A high incidence of MSH6 mutations in Amsterdam criteria II-negative families tested in a diagnostic setting. Gut. 2008, 57:1539-44.
38. van Dijk DA, Oostindier MJ, Kloosterman-Boele WM. Family history is neglected in the work-up of patients with colorectal cancer: a quality assessment using cancer registry data. Fam Cancer. 2007, 6:131-4.
39. Overbeek LI, Hoogerbrugge N, van Krieken JH. Most patients with colorectal tumors at young age do not visit a cancer genetics clinic. Dis Colon Rectum. 2008, 51:1249-54.
40. Van Lier MG, De Wilt JH, Wagemakers JJ. Underutilization of microsatellite instability analysis in colorectal cancer patients at high risk for Lynch syndrome. Scand J Gastroenterol. 2009, 44:600-4.
41. Kievit W, de Bruin JH, Adang EM. Cost effectiveness of a new strategy to identify HNPCC patients. Gut. 2005, 54:97-102.
42. de Bruin JH, Ligtenberg MJ, Nagengast FM. Optimizing the detection of hereditary non-polyposis colorectal cancer: an update. Scand J Gastroenterol Suppl. 2006, 243:146-52.
43. Wijnen JT, Vasen HF, Khan PM. Clinical findings with implications for genetic testing in families with clustering of colorectal cancer. N Engl J Med. 1998, 339:511-8.
44. Barnetson RA, Tenesa A, Farrington SM. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med. 2006, 354:2751-63.
45. Balmana J, Stockwell DH, Steyerberg EW. Prediction of MLH1 and MSH2 mutations in Lynch syndrome. JAMA. 2006, 296:1469-78.
46. Chen S, Wang W, Lee S. Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA. 2006, 296:1479-87.
47. Peltomaki P, Vasen H. Mutations associated with HNPCC predisposition-Update of ICG-HNPCC/INSiGHT mutation database. Dis Markers. 2004, 20:269-76.
48. Vasen HF, Boland CR. Progress in genetic testing, classification, and identification of Lynch syndrome. JAMA. 2005, 293:2028-30.
49. Miyaki M, Konishi M, Tanaka K. Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nat Genet. 1997, 17:271-2.
50. Hendriks YM, Jagmohan-Changur S, van der Klift HM. Heterozygous mutations in PMS2 cause hereditary nonpolyposis colorectal carcinoma (Lynch syndrome). Gastroenterology. 2006, 130:312-22.
51. Knudson AG. Two genetic hits (more or less) to cancer. Nat Rev Cancer. 2001, 1:157-62.
52. Chung DC, Rustgi AK. DNA mismatch repair and cancer. Gastroenterology. 1995, 109:1685-99.
53. Papadopoulos N, Nicolaides NC, Liu B. Mutations of GTBP in genetically unstable cells. Science. 1995, 268:1915-7.
54. Baker SM, Bronner CE, Zhang L. Male mice defective in the DNA mismatch repair gene PMS2 exhibit abnormal chromosome synapsis in meiosis. Cell. 1995, 82:309-19.
55. Fishel R, Ewel A, Lescoe MK. Purified human MSH2 protein binds to DNA containing mismatched nucleotides. Cancer Res. 1994, 54:5539-42.
56. Yang Q, Zhang R, Wang XW. The mismatch DNA repair heterodimer, hMSH2/6, regulates BLM helicase. Oncogene. 2004, 23:3749-56.
57. Genschel J, Bazemore LR, Modrich P. Human exonuclease I is required for 5′ and 3′ mismatch repair. J Biol Chem. 2002, 277:13302-11.
58. Gruber SB. New developments in Lynch syndrome (hereditary nonpolyposis colorectal cancer) and mismatch repair gene testing. Gastroenterology. 2006, 130:577-87.
59. Ionov Y, Peinado MA, Malkhosyan S. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature. 1993, 363:558-61.
60. Umar A, Boyer JC, Thomas DC. Defective mismatch repair in extracts of colorectal and endometrial cancer cell lines exhibiting microsatellite instability. J Biol Chem. 1994, 269:14367-70.
61. Aaltonen LA, Peltomaki P, Mecklin JP. Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res. 1994, 54:1645-8.
62. Boland CR, Thibodeau SN, Hamilton SR. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998, 58:5248-57.
63. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003, 348:919-32.
64. Kane MF, Loda M, Gaida GM. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 1997, 57:808-11.
65. Herman JG, Umar A, Polyak K. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA. 1998, 95:6870-5.
66. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003, 349:2042-54.
67. Wang L, Cunningham JM, Winters JL. BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res. 2003, 63:5209-12.
68. Miyaki M, Iijima T, Yamaguchi T. Both BRAF and KRAS mutations are rare in colorectal carcinomas from patients with hereditary nonpolyposis colorectal cancer. Cancer Lett. 2004, 211:105-9.
69. McGivern A, Wynter CV, Whitehall VL. Promoter hypermethylation frequency and BRAF mutations distinguish hereditary non-polyposis colon cancer from sporadic MSI-H colon cancer. Fam Cancer. 2004, 3:101-7.
70. Kambara T, Simms LA, Whitehall VL. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut. 2004, 53:1137-44.
71. Domingo E, Laiho P, Ollikainen M. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet. 2004, 41:664-8.
72. Deng G, Bell I, Crawley S. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res. 2004, 10:191-5.
73. Young J, Barker MA, Simms LA. Evidence for BRAF mutation and variable levels of microsatellite instability in a syndrome of familial colorectal cancer. Clin Gastroenterol Hepatol. 2005, 3:254-63.
74. Loughrey MB, Waring PM, Tan A. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer. Fam Cancer. 2007, 6:301-10.
75. Bessa X, Balleste B, Andreu M. A prospective, multicenter, population-based study of BRAF mutational analysis for Lynch syndrome screening. Clin Gastroenterol Hepatol. 2008, 6:206-14.
76. Nagasaka T, Koi M, Kloor M. Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer. Gastroenterology. 2008, 134:1950-60. 1960
77. Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology. 2008, 135:1079-99.
78. Gazzoli I, Loda M, Garber J. A hereditary nonpolyposis colorectal carcinoma case associated with hypermethylation of the MLH1 gene in normal tissue and loss of heterozygosity of the unmethylated allele in the resulting microsatellite instability-high tumor. Cancer Res. 2002, 62:3925-8.
79. Suter CM, Martin DI, Ward RL. Germline epimutation of MLH1 in individuals with multiple cancers. Nat Genet. 2004, 36:497-501.
80. Miyakura Y, Sugano K, Akasu T. Extensive but hemiallelic methylation of the hMLH1 promoter region in early-onset sporadic colon cancers with microsatellite instability. Clin Gastroenterol Hepatol. 2004, 2:147-56.
81. Hitchins M, Williams R, Cheong K. MLH1 germline epimutations as a factor in hereditary nonpolyposis colorectal cancer. Gastroenterology. 2005, 129:1392-9.
82. Hitchins MP, Wong JJ, Suthers G. Inheritance of a cancer-associated MLH1 germ-line epimutation. N Engl J Med. 2007, 356:697-705.
83. Valle L, Carbonell P, Fernandez V. MLH1 germline epimutations in selected patients with early-onset non-polyposis colorectal cancer. Clin Genet. 2007, 71:232-7.
84. Morak M, Schackert HK, Rahner N. Further evidence for heritability of an epimutation in one of 12 cases with MLH1 promoter methylation in blood cells clinically displaying HNPCC. Eur J Hum Genet. 2008, 16:804-11.
85. Hitchins MP, Ward RL. Constitutional (germline) MLH1 epimutation as an aetiological mechanism for hereditary non-polyposis colorectal cancer. J Med Genet. 2009, 46:793-802.
86. Dobrovic A, Kristensen LS. DNA methylation, epimutations and cancer predisposition. Int J Biochem Cell Biol. 2009, 41:34-9.
87. Ligtenberg MJ, Kuiper RP, Chan TL. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1. Nat Genet. 2009, 41:112-7.
88. Dietmaier W, Wallinger S, Bocker T. Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. Cancer Res. 1997, 57:4749-56.
89. Thibodeau SN, French AJ, Cunningham JM. Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1. Cancer Res. 1998, 58:1713-8.
90. Veigl ML, Kasturi L, Olechnowicz J. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci USA. 1998, 95:8698-702.
91. Jass JR, Walsh MD, Barker M. Distinction between familial and sporadic forms of colorectal cancer showing DNA microsatellite instability. Eur J Cancer. 2002, 38:858-66.
92. Laiho P, Launonen V, Lahermo P. Low-level microsatellite instability in most colorectal carcinomas. Cancer Res. 2002, 62:1166-70.
93. Pawlik TM, Raut CP, Rodriguez-Bigas MA. Colorectal carcinogenesis: MSI-H versus MSI-L. Dis Markers. 2004, 20:199-206.
94. Gryfe R, Kim H, Hsieh ET. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med. 2000, 342:69-77.
95. Wright CM, Dent OF, Barker M. Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer. Br J Surg. 2000, 87:1197-202.
96. Chang EY, Dorsey PB, Frankhouse J. Combination of microsatellite instability and lymphocytic infiltrate as a prognostic indicator in colon cancer. Arch Surg. 2009, 144:511-5.
97. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science. 1993, 260:816-9.
98. Ribic CM, Sargent DJ, Moore MJ. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003, 349:247-57.
99. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005, 23:609-18.
100. Jover R, Zapater P, Castells A. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut. 2006, 55:848-55.
101. Chialina SG, Fornes C, Landi C. Microsatellite instability analysis in hereditary non-polyposis colon cancer using the Bethesda consensus panel of microsatellite markers in the absence of proband normal tissue. BMC Med Genet. 2006, 7. 5
102. Suraweera N, Duval A, Reperant M. Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology. 2002, 123:1804-11.
103. Bacher JW, Flanagan LA, Smalley RL. Development of a fluorescent multiplex assay for detection of MSI-High tumors. Dis Markers. 2004, 20:237-50.
104. Akiyama Y, Sato H, Yamada T. Germ-line mutation of the hMSH6/GTBP gene in an atypical hereditary nonpolyposis colorectal cancer kindred. Cancer Res. 1997, 57:3920-3.
105. Berends MJ, Wu Y, Sijmons RH. Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant. Am J Hum Genet. 2002, 70:26-37.
106. Xicola RM, Llor X, Pons E. Performance of different microsatellite marker panels for detection of mismatch repair-deficient colorectal tumors. J Natl Cancer Inst. 2007, 99:244-52.
107. Halvarsson B, Lindblom A, Rambech E. Microsatellite instability analysis and/or immunostaining for the diagnosis of hereditary nonpolyposis colorectal cancer. Virchows Arch. 2004, 444:135-41.
108. Chen PC, Dudley S, Hagen W. Contributions by MutL homologues Mlh3 and Pms2 to DNA mismatch repair and tumor suppression in the mouse. Cancer Res. 2005, 65:8662-70.
109. Cannavo E, Marra G, Sabates-Bellver J. Expression of the MutL homologue hMLH3 in human cells and its role in DNA mismatch repair. Cancer Res. 2005, 65:10759-66.
110. Acharya S, Wilson T, Gradia S. hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6. Proc Natl Acad Sci USA. 1996, 93:13629-34.
111. Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn. 2008, 10:293-300.
112. Poley JW, Wagner A, Hoogmans MM. Biallelic germline mutations of mismatch-repair genes: a possible cause for multiple pediatric malignancies. Cancer. 2007, 109:2349-56.
113. Capel E, Flejou JF, Hamelin R. Assessment of MLH1 promoter methylation in relation to gene expression requires specific analysis. Oncogene. 2007, 26:7596-600.
114. Schouten JP, McElgunn CJ, Waaijer R. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 2002, 30. e57
115. Heinmoller E, Renke B, Beyser K. Pitfalls in diagnostic molecular pathology-significance of sampling error. Virchows Arch. 2001, 439:504-11.
116. Muller A, Giuffre G, Edmonston TB. Challenges and pitfalls in HNPCC screening by microsatellite analysis and immunohistochemistry. J Mol Diagn. 2004, 6:308-15.
117. Mangold E, Pagenstecher C, Friedl W. Tumours from MSH2 mutation carriers show loss of MSH2 expression but many tumours from MLH1 mutation carriers exhibit weak positive MLH1 staining. J Pathol. 2005, 207:385-95.
118. Muller W, Burgart LJ, Krause-Paulus R. The reliability of immunohistochemistry as a prescreening method for the diagnosis of hereditary nonpolyposis colorectal cancer (HNPCC)-results of an international collaborative study. Fam Cancer. 2001, 1:87-92.
119. Overbeek LI, Ligtenberg MJ, Willems RW. Interpretation of immunohistochemistry for mismatch repair proteins is only reliable in a specialized setting. Am J Surg Pathol. 2008, 32:1246-51.
120. Matsubara N. Diagnostic application of hMLH1 methylation in hereditary non-polyposis colorectal cancer. Dis Markers. 2004, 20:277-82.
121. Deng G, Chen A, Hong J. Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. Cancer Res. 1999, 59:2029-33.
122. Esteller M, Fraga MF, Guo M. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet. 2001, 10:3001-7.
123. Rahner N, Friedrichs N, Steinke V. Coexisting somatic promoter hypermethylation and pathogenic MLH1 germline mutation in Lynch syndrome. J Pathol. 2008, 214:10-6.
124. Cunningham JM, Christensen ER, Tester DJ. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res. 1998, 58:3455-60.
125. Kuismanen SA, Holmberg MT, Salovaara R. Epigenetic phenotypes distinguish microsatellite-stable and -unstable colorectal cancers. Proc Natl Acad Sci USA. 1999, 96:12661-6.
126. Kuismanen SA, Holmberg MT, Salovaara R. Genetic and epigenetic modification of MLH1 accounts for a major share of microsatellite-unstable colorectal cancers. Am J Pathol. 2000, 156:1773-9.
127. Wheeler JM, Loukola A, Aaltonen LA. The role of hypermethylation of the hMLH1 promoter region in HNPCC versus MSI+ sporadic colorectal cancers. J Med Genet. 2000, 37:588-92.
128. Potocnik U, Glavac D, Golouh R. Causes of microsatellite instability in colorectal tumors: implications for hereditary non-polyposis colorectal cancer screening. Cancer Genet Cytogenet. 2001, 126:85-96.
129. Ollikainen M, Hannelius U, Lindgren CM. Mechanisms of inactivation of MLH1 in hereditary nonpolyposis colorectal carcinoma: a novel approach. Oncogene. 2007, 26:4541-9.
130. Ramsoekh D, van Leerdam ME, Wagner A. Review article: detection and management of hereditary non-polyposis colorectal cancer (Lynch syndrome). Aliment Pharmacol Ther. 2007, 26:101-11.
131. Ferreira AM, Westers H, Wu Y. Do microsatellite instability profiles really differ between colorectal and endometrial tumors. Genes Chromosomes Cancer. 2009, 48:552-7.
132. de Leeuw WJ, Dierssen J, Vasen HF. Prediction of a mismatch repair gene defect by microsatellite instability and immunohistochemical analysis in endometrial tumours from HNPCC patients. J Pathol. 2000, 192:328-35.
133. Hewitt MJ, Wood N, Quinton ND. The detection of microsatellite instability in blind endometrial samples-a potential novel screening tool for endometrial cancer in women from hereditary nonpolyposis colorectal cancer families. Int J Gynecol Cancer. 2006, 16:1393-400.